Can Biologic Agents Improve Treatment Success in Obese Patients With Psoriasis Vulgaris: A Retrospective Review of 320 Patients With Psoriasis Vulgaris

Atıl Avcı; Deniz Avcı; Yılmaz Ulaş; Ragıp Ertaş

doi:10.5826/dpc.1401a58

Can Biologic Agents Improve Treatment Success in Obese Patients With Psoriasis Vulgaris: A Retrospective Review of 320 Patients With Psoriasis Vulgaris

Authors

Atıl Avcı Department of Dermatology, Kayseri City Education and Research Hospital, Kayseri, Turkey
Deniz Avcı Department of Internal Medicine, Kayseri City Education and Research Hospital, Kayseri, Turkey
Yılmaz Ulaş Department of Dermatology, Kayseri City Education and Research Hospital, Kayseri, Turkey
Ragıp Ertaş Department of Dermatology, Kayseri City Education and Research Hospital, Kayseri, Turkey

Keywords:

psoriasis, obesity, body mass index, biological agents

Abstract

Introduction: Obesity plays a major role in the development of many inflammatory disorders including psoriasis.

Objectives: We aimed to demonstrate how treatment responses change according to body mass index among patients with psoriasis.

Methods: In our study, Psoriasis Area and Severity Index (PASI) 75 and PASI 90 responses were assessed at baseline and at months 1 and 3 among patients who received TNF-α inhibitors, ustekinumab, IL-17 blockers, and IL-23 blockers. The same responses were also assessed with methotrexate and acitretin for a comparison group. Analyses were performed retrospectively.

Results: The study included 317 patients who received 222 biological and 95 conventional treatments. In the group with BMI of ≥30, the proportion of patients who achieved PASI 75 response was 40.0% (n=26) at month 1 and 55.4% (n=36) at month 3. The proportion of patients who achieved PASI 90 response was 33.8% (n=22) at month 1 and 44.6% (n=29) at month 3 among those receiving biological agents. Improvement was significantly more difficult among obese patients. While the presence of joint involvement affected the success of treatment among obese patients with psoriasis, no relationships were found for smoking, the presence of concomitant psychiatric diseases, or the presence of pruritus in psoriasis.

Conclusion: Biological agents were more successful in achieving PASI 75 and PASI 90 responses in both non-obese and obese individuals. Based on our study, among biological agents, IL-17 and IL-23 inhibitors may be more successful among obese individuals, but neither of them shows superiority over the other.

References

Vizzardi E, Raddino R, Teli M, Gorga E, Brambilla G, Dei Cas L. Psoriasis and cardiovascular diseases. Acta Cardiol. 2010;65(3):337-340. DOI: 10.2143/AC.65.3.2050351. PMID: 20666273.

Chen YJ, Wu CY, Chen TJ, et al. The risk of cancer in patients with psoriasis: a population-based cohort study in Taiwan. J Am Acad Dermatol. 2011;65(1):84-91. DOI: 10.1016/j.jaad.2010.04.046. PMID: 21458106.

González-Parra S, Daudén E. Psoriasis and Depression: The Role of Inflammation. Actas Dermosifiliogr (Engl Ed). 2019;110(1):12-19. DOI: 10.1016/j.ad.2018.05.009. PMID: 30509759.

Sales R, Torres T. Psoriasis and metabolic syndrome. Acta Dermatovenerol Croat. 2014;22(3):169-174. PMID: 25230056.

Jensen P, Skov L. Psoriasis and Obesity. Dermatology. 2016;232(6):633-639. DOI: 10.1159/000455840. PMID: 28226326.

Anghel F, Nitusca D, Cristodor P. Body Mass Index Influence for the Personalization of the Monoclonal Antibodies Therapy for Psoriasis. Life (Basel). 2021;11(12):1316. DOI: 10.3390/life11121316. PMID: 34947847. PMCID: PMC8703749.

Ogawa K, Okada Y. The current landscape of psoriasis genetics in 2020. J Dermatol Sci. 2020;99(1):2-8. DOI: 10.1016/j.jdermsci.2020.05.008. PMID: 32536600.

Orloff JN, Kaminetsky JR, Aziz M. Psoriasis and Obesity: A Review of the Current Literature. SKIN The Journal of Cutaneous Medicine. 2018;2(6). DOI: 10.25251/skin.2.6.4.

Barros G, Duran P, Vera I, Bermúdez V. Exploring the Links between Obesity and Psoriasis: A Comprehensive Review. Int J Mol Sci. 2022;23(14):7499. DOI: 10.3390/ijms23147499. PMID: 35886846. PMCID: PMC9321445.

Armstrong AW, Read C. Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review. JAMA. 2020;323(19):1945-1960. DOI: 10.1001/jama.2020.4006. PMID: 32427307.

Kong Y, Zhang S, Wu R, et al. New insights into different adipokines in linking the pathophysiology of obesity and psoriasis. Lipids Health Dis. 2019;18(1):171. DOI: 10.1186/s12944-019-1115-3. PMID: 31521168. PMCID: PMC6745073.

Snekvik I, Smith CH, Nilsen TIL, et al. Obesity, Waist Circumference, Weight Change, and Risk of Incident Psoriasis: Prospective Data from the HUNT Study. J Invest Dermatol. 2017;137(12):2484-2490. DOI: 10.1016/j.jid.2017.07.822. PMID: 28780086.

Ko SH, Chi CC, Yeh ML, Wang SH, Tsai YS, Hsu MY. Lifestyle changes for treating psoriasis. Cochrane Database Syst Rev. 2019;7(7):CD011972. DOI: 10.1002/14651858.CD011972.pub2. PMID: 31309536. PMCID: PMC6629583.

Llamas-Velasco M, Ovejero-Merino E, Salgado-Boquete L. Obesidad: factor de riesgo para psoriasis y COVID-19 [Obesity - A Risk Factor for Psoriasis and COVID-19]. Actas Dermosifiliogr. 2021;112(6):489-494. DOI: 10.1016/j.ad.2020.12.001. PMID: 34629472. PMCID: PMC7977150.

Özyurt K, Avcı A, Ertaş R, Ulaş Y, Akkuş MR, Özlü E, et al. Psortaksis: Kayseri sağlık uygulama ve araştırma merkezi dermatoloji kliniği’nde kullanılan yeni bir psoriasis hasta kayıt sistemi. Turk Dermatoloji Derg. 2018;12(1):23–7. DOI: 10.4274/tdd.3418

Sun L, Liu W, Zhang LJ. The Role of Toll-Like Receptors in Skin Host Defense, Psoriasis, and Atopic Dermatitis. J Immunol Res. 2019;2019:1824624. DOI: 10.1155/2019/1824624. PMID: 31815151. PMCID: PMC6877906.

Zhang LJ. Type1 Interferons Potential Initiating Factors Linking Skin Wounds With Psoriasis Pathogenesis. Front Immunol. 2019;10:1440. DOI: 10.3389/fimmu.2019.01440. PMID: 31293591. PMCID: PMC6603083.

Guo Z, Yang Y, Liao Y, Shi Y, Zhang LJ. Emerging Roles of Adipose Tissue in the Pathogenesis of Psoriasis and Atopic Dermatitis in Obesity. JID Innov. 2021;2(1):100064. DOI: 10.1016/j.xjidi.2021.100064. PMID: 35024685. PMCID: PMC8659781.

Budu-Aggrey A, Brumpton B, Tyrrell J, et al. Evidence of a causal relationship between body mass index and psoriasis: A mendelian randomization study. PLoS Med. 2019;16(1):e1002739. DOI: 10.1371/journal.pmed.1002739. PMID: 30703100. PMCID: PMC6354959.

Snekvik I, Smith CH, Nilsen TIL, et al. Obesity, Waist Circumference, Weight Change, and Risk of Incident Psoriasis: Prospective Data from the HUNT Study. J Invest Dermatol. 2017;137(12):2484-2490. DOI: 10.1016/j.jid.2017.07.822. PMID: 28780086.

Fleming P, Kraft J, Gulliver WP, Lynde C. The Relationship of Obesity With the Severity of Psoriasis: A Systematic Review. J Cutan Med Surg. 2015;19(5):450-456. DOI: 10.1177/1203475415586332. PMID: 26271963.

Hafidi ME, Buelna-Chontal M, Sánchez-Muñoz F, Carbó R. Adipogenesis: A Necessary but Harmful Strategy. Int J Mol Sci. 2019;20(15):3657. DOI: 10.3390/ijms20153657. PMID: 31357412. PMCID: PMC6696444.

Kyriakou A, Patsatsi A, Sotiriadis D, Goulis DG. Serum Leptin, Resistin, and Adiponectin Concentrations in Psoriasis: A Meta-Analysis of Observational Studies. Dermatology. 2017;233(5):378-389. DOI: 10.1159/000481882. PMID: 29232663.

Li RC, Krishnamoorthy P, DerOhannessian S, et al. Psoriasis is associated with decreased plasma adiponectin levels independently of cardiometabolic risk factors. Clin Exp Dermatol. 2014;39(1):19-24. DOI: 10.1111/ced.12250. PMID: 24341476. PMCID: PMC3869034.

Puig L. Obesity and psoriasis: body weight and body mass index influence the response to biological treatment. J Eur Acad Dermatol Venereol. 2011;25(9):1007-1011. DOI: 10.1111/j.1468-3083.2011.04065.x. PMID: 21492252.

Sbidian E, Chaimani A, Garcia-Doval I, et al. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane Database Syst Rev. 202;4(4):CD011535. DOI: 10.1002/14651858.CD011535.pub4. PMID: 33871055. PMCID: PMC8408312.

Bai F, Li GG, Liu Q, Niu X, Li R, Ma H. Short-Term Efficacy and Safety of IL-17, IL-12/23, and IL-23 Inhibitors Brodalumab, Secukinumab, Ixekizumab, Ustekinumab, Guselkumab, Tildrakizumab, and Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials. J Immunol Res. 2019;2019:2546161. DOI: 10.1155/2019/2546161. PMID: 31583255. PMCID: PMC6754904.

George LA, Gadani A, Cross RK, Jambaulikar G, Ghazi LJ. Psoriasiform Skin Lesions Are Caused by Anti-TNF Agents Used for the Treatment of Inflammatory Bowel Disease. Dig Dis Sci. 2015;60(11):3424-3430. DOI: 10.1007/s10620-015-3763-0. PMID: 26115749.

Yang M, Liu W, Deng Q, Liang Z, Wang Q. The incidence of psoriasis among smokers and/or former smokers inflammatory bowel diseases patients treated with tumor necrosis factor antagonist: A systematic review and meta-analysis. Medicine (Baltimore). 2021;100(42):e27510. DOI: 10.1097/MD.0000000000027510. PMID: 34678884. PMCID: PMC8542134.

Pompili M, Innamorati M, Trovarelli S, et al. Suicide risk and psychiatric comorbidity in patients with psoriasis. J Int Med Res. 2016;44(1 suppl):61-66. DOI: 10.1177/0300060515593253. PMID: 27683142. PMCID: PMC5536523.

Pouw JN, Jacobs ME, Balak DMW, van Laar JM, Welsing PMJ, Leijten EFA. Do Patients with Psoriatic Arthritis Have More Severe Skin Disease than Patients with Psoriasis Only? A Systematic Review and Meta-Analysis. Dermatology. 2022;238(6):1108-1119. DOI: 10.1159/000524231. PMID: 35551372. PMCID: PMC9677854.

Rouzaud M, Sevrain M, Villani AP, et al. Is there a psoriasis skin phenotype associated with psoriatic arthritis? Systematic literature review. J Eur Acad Dermatol Venereol. 2014;28 Suppl 5:17-26. DOI: 10.1111/jdv.12562. PMID: 24985559.

Haroon M, Gallagher P, FitzGerald O. Diagnostic delay of more than 6 months contributes to poor radiographic and functional outcome in psoriatic arthritis. Ann Rheum Dis. 2015;74(6):1045-1050. DOI: 10.1136/annrheumdis-2013-204858. PMID: 24525911.

Scher JU, Ogdie A, Merola JF, Ritchlin C. Preventing psoriatic arthritis: focusing on patients with psoriasis at increased risk of transition. Nat Rev Rheumatol. 2019;15(3):153-166. DOI: 10.1038/s41584-019-0175-0. PMID: 30742092.